




מדינת ישראל
STATE OF ISRAEL

PCT/IL 03 / 00204



Ministry of Justice
Patent Office

משרד המשפטים
לשכת הפטנטים

This is to certify that
annexed hereto is a true
copy of the documents as
originally deposited with
the patent application
of which particulars are
specified on the first page
of the annex.

זאת לתעודה כי
רצופים בזה העתקים
נכונים של המסמכים
שהופקדו לכתחילה
עם הבקשה לפטנט
לפי הפרטים הרשומים
בעמוד הראשון של
הנספח.

PRIORITY DOCUMENT
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH
RULE 17.1(a) OR (b)


This 02-04-2003 היום

החתימה
של המזכיר

רשם הפטנטים

Commissioner of Patents

נתאשר
Certified



לשימוש הלשכה
For Office Use

מספר: Number	148665
תאריך: Date	
הוקדם/נדחה: Ante/Post-dated	13-03-2002

חוק הפטנטים, תשכ"ז -
PATENTS LAW, 5727-1967

בקשה לפטנט
Application For Patent

אני, (שם המבקש, מענו ולגבי גוף מאגדת מקום התאגדותו)
I, (Name and address of applicant, and in case of body corporate-place of incorporation)

ידע חברה למחקר ופיתוח בע"מ, חברה ישראלית מליד מכון ויצמן למדע, ת"ד 95, רחובות 76100, ישראל
Yeda Research And Development Co. Ltd., Israeli Company of At The Weizmann Institute Of Science,
P.O.Box 95, Rehovot 76100, ISRAEL

שמה הוא Assignment העברה בעל אמצאה מכח
of an invention the title of which is Owner, by virtue of

נגזרות של 1,3-פרופאנדיאול פוספאט ציקלי ופעילותם כמעוררי תאים


(בעברית)
(Hebrew)

Derivatives of 1,3-cyclic propandiol phosphate and their action as cell stimulants

(באנגלית)
(English)

Hereby apply for a patent to be granted to me in respect thereof.

מבקש בזאת כי ינתן לי עליה פטנט

* בקשת חלוקה Application of Division		* בקשת פטנט מוסף Appl. for Patent of Addition		דרישת דין קדימה Priority Claim	
מבקשת פטנט from application		* לבקשה/לפטנט to Patent/Appl.		מספר/סימן Number/Mark	תאריך Date
No.	מס'	No.	מס'		מדינת האירוע Convention Country
Dated	מיום	Dated	מיום		
P.O.A.: General		כללי			
filed in case		הוגש בעניין			
C. 135386		המען למסירת מסמכים בישראל Address for Service in Israel			
REINHOLD COHN AND PARTNERS Patent Attorneys P.O.B. 4060, Tel-Aviv		ריינהולד כהן ושותפיו עורכי פטנטים ת"ד 4060, תל-אביב			
חתימת המבקש Signature of Applicant		בשם המבקשים, ריינהולד כהן ושותפיו ע"י:		שנת 2002 Year	
				March of 12 This	
				לשימוש הלשכה For Office Use	

טופס זה כשהוא מוטבע בחותם לשכת הפטנטים ומושלם במספר ובתאריך ההגשה, הנו אישור להגשת הבקשה שפרטיה רשומים לעיל.
This form, impressed with the Seal of the Patent Office and indicating the number and date of filing, certifies the filing of the application the particulars of which are set out above.

* מחק את המיותר
Delete whatever is inapplicable

נגזרות של 1,3-פרופאנדיאול פוספאט ציקלי ופעילותם כמעוררי תאים

Derivatives of 1,3-cyclic propandiol phosphate and their action as cell stimulants

Yeda Research And Development Co. Ltd.

ידע חברה למחקר ופיתוח בע"מ

C. 135386

DERIVATIVES OF 1,3-CYCLIC PROPANDIOL PHOSPHATE AND THEIR ACTION AS CELL STIMULANTS

5

FIELD OF THE INVENTION

This invention relates to 1,3-cyclic propandiol phosphate derivatives, pharmaceutical compositions comprising them and use thereof as cell stimulants.

PRIOR ART

10 The following is a list of references which is intended for a better understanding of the background of the present invention.

15 Boyd, R.K., De Freitas, A.S.W., Hoyle, J., McCulloch, A.W., McInnes, A.G., Rogerson, A. and Walter, J.A., *J. Biol. Chem.*, 262:12406-12408 (1987).

Clarke, N. and Dawson, R.M.C., *Biochem. J.*, 216:867-874 (1976).

Dawson, R.M.C., *Ann. Rept. Progr. Chem.* 55:365, (1958).

20 Dawson, R.M.C., Freinkel, N., Jungalwala, F.B. and Clarke, N., *Biochem. J.*, 122:605-607, (1971).

Forrest, H.S. and Todd, A.R., *J. Chem. Soc.*, 1950, 3925, (1950).

25 Friedman, P., Haimovitz, R., Markman, O., Roberts, M.F. and Shinitzky, M., Conversion of lysophospholipids to cyclic lysophosphatidic acid by phospholipase, *D.J. Biol. Chem.*, 271:953-957 (1996).

30 Hagg, T. and Varon, S., *Proc. Natl. Acad. Sci. USA* 90:6315-6319, (1993).

Kennedy and Weiss, *J. Biol. Chem.*, 222:193 (1956).

Knusel, B., *et al.*, *Neurosci.*, 10:558-570, (1990).

35 Knusel, *et al.*, *Proc. Natl. Acad. Sci. USA*, 88:961-965 (1991).

Leloir, L.F., *Biochem. Biophys. J.*, **33**:186 (1951).

Linn, L.F.H., *et al.*, *Science*, **260**:1130-1134 (1993).

5 Markham, R. and Smith, J.D., *Biochem. J.*, **52**:552- (1952).

Shinitzky, M., Friedman, P. and Haimovitz, R., Formation of 1,3-cyclic glycerophosphate by the action of phospholipase C on phosphatidylglycerol, *J.*

10 *Biol. Chem.*, **268**:14109-14115 (1993).

Shinitzky, M, Haimovitz, R, Nemas, M, Cahana, N, Mamillapalli, R, Seger, R (2000) Induction of intracellular signalling by cyclic glycerophosphates and their deoxy analogues. *Eur. J. Biochem.* 267: 2547

15 Su, B., Kappler, F., Szwergold, B.S. and Brown, T.R., *Cancer Res.*, **53**:1751-1754, (1993).

Tomac, A., *et al.*, *Nature*, **373**:335-339 (1995).

Ukita, T., Bates, N.A. and Carter, H.E., *J. Biol. Chem.*, **216**:867-874, (1955).

20 Shinitzky, M. WO 00/57,865.

BACKGROUND OF THE INVENTION

L- α -glycerophosphate (α GP), a key constituent in phospholipid metabolism (Kennedy and Weiss, 1956), is abundant in most biological tissues (Dawson, 25 1958). β -Glycerophosphate (β GP) is a product of enzymatic (Ukita *et al.*, 1955) and alkaline (Clarke and Dawson, 1976) hydrolysis of phospholipids and is formed through the cyclic phosphodiester intermediate 1,2-cyclic glycerophosphate (1,2 cGP) (Ukita *et al.*, 1955; Clarke and Dawson, 1976). 1,2 cGP has been detected in algae species (Boyd *et al.*, 1987) as well as in human cancer tissues (Su *et al.*, 30 1993). Similarly, α GP can in principle adopt the cyclic form 1,3-cyclic glycerophosphate (1,3 cGP). This compound has been shown to be formed as an intermediate in the phospholipase C hydrolysis of phosphatidyl glycerol (PG) (Shinitzky *et al.*, 1993) and upon further hydrolysis is converted to α GP.

A six-membered cyclic phosphate of foremost biological importance is cyclic AMP. The ring of cyclic AMP is actually a derivative of 1,3 cGMP backbone. Other cyclic phosphates which were detected in biological systems include glucose cyclic phosphodiester (Leloir, 1951), 2',3'-cyclic phosphodiester (Markham and
5 Smith, 1952), riboflavin-4',5'-cyclic phosphodiester (Forrest and Todd, 1950), myoinositol-1,2-cyclic phosphodiester (Dawson *et al.*, 1971) and cyclic lysophosphatidic acid (Friedman *et al.*, 1996).

Except for cyclic AMP and cyclic GMP, which have been extensively studied, no specific biological activities have been so far assigned to the other
10 biological cyclic phosphates.

There are several kinds of disorders and diseases, which result from deterioration of areas of the brain and loss of neurons. One example of such diseases are neurodegenerative diseases such as Parkinson's disease (PD). Such diseases often involve degeneration of dopamine-producing neurons. Current
15 therapeutic methods are mostly aimed at continuous stimulation of dopamine receptors by drugs, which, although initially providing symptomatic relief, gradually lose effectiveness. Furthermore, such drugs do not prevent the progressive degeneration of dopaminergic neurons characteristics of such diseases.

A large number of growth factors such as nerve growth factor (NGF), basic
20 fibroblast growth factor (bFGF), epidermal growth factor (EGF), insulin-like growth factor, brain derived growth factor and glial derived neurotrophic factor (Knusel B., *et al.*, 1990; Knusel *et al.*, 1991; Linn *et al.*, 1993) stimulate dopaminergic neuron survival and differentiation *in vitro*. In animal models involving induction of Parkinson's disease, the induced animals show improved
25 behavior and an increase in tyrosine hydroxylase (TH), the key enzyme in the dopamine production pathway immunoreactivity when treated with factors like GDNF (Tomic, A. *et al.* 1995) and ciliary neurotrophic factor (CNTF) (Hagg, T. and Varon 1993).

GLOSSARY

The following is an explanation of some terms used above and in the following description and claims:

5

CPP – the 1,3-cyclic propandiol phosphates derivatives used in the present invention.

Target cells – any cells, which have the potential to mature into neural cells.

10 Non-limiting examples of such cells are PC12 and primary brain cells.

Substantially maintaining - this term relates to the capability of analogs to promote the activity carried out by the cyclic glycerophosphate from which they were derived to a certain extent. The analog's activity will be considered to be
15 substantially maintained wherein the activity is 30% or above, preferably 50% or above, more preferably 70% or above, and most preferably 90% or above the level of the activity of the cyclic glycerophosphate.

Effective amount – wherein the method of the invention is intended for
20 prevention of a non-desired condition, the term "*effective amount*" should then be understood as meaning an amount of the active compound which, when administered to an individual, results in the prevention of the appearance of the said condition. Prevention of such a condition, e.g. a neurodegenerative condition, may be required prior to the appearance of any symptoms of a disease, e.g. in
25 individuals having a high disposition of developing the disease, or when the compositions are used for the treatment of nerve rescue which is expected after nerve injury. Wherein the compositions or methods are intended for treatment of an ongoing non-desired condition, the term "*effective amount*" should then be understood as meaning an amount of the active compound which is effective in

ameliorating or preventing the enhancement of the treated condition and related symptoms.


Neural promoting activity – this term encompasses a variety of neural related activities which may be promoted in target cells upon their contact with the *CPP* used in the invention. Such activities include but are not limited to promotion of nerve growth, provision of dopaminotrophic supporting environment in a diseased brain, prevention of nerve degeneration, and nerve rescue.

Prevention or treatment – the term prevention of disorders or diseases is to be understood in accordance with the invention as a reduction in the probability of the appearance of such disorders or diseases in an individual having a high predisposition of developing such disorders or diseases, reducing the extent of the symptoms associated with such disorders and diseases when they occur or completely preventing their appearance.

SUMMARY OF THE INVENTION

In accordance with the invention new derivatives of 1,3-cyclic propandiol phosphate are provided that are capable of stimulating cells.

The present invention thus provides, by a first of its aspects, a compound of formula I



wherein

n is 0 or 1;

X is hydrogen, O-R, NH-R or N-(C=O)-R;

Y is O-R₁, NH-R₁;

R is hydrogen, linear or branched alkyl, linear or branched acyl, substituted or non-substituted aryl or araalkyl residue;

R₁ is hydrogen, linear or branched alkyl, linear or branched acyl, substituted or
5 non-substituted aryl, alkylcarboxy ester or alkyl-N-R₂R₃;

R₂ and R₃ are independently hydrogen or an alkyl group;

provided that when X is hydrogen Y is not O-R₁ wherein R₁ is hydrogen, alkyl or aryl.

As used herein the term "*alkyl*" refers to an alkyl group having from 1 to 24
10 carbon atoms, e.g. preferably from 3 carbon atoms to 20 carbon atoms, most preferably from 5 carbon atoms to 15 carbon atoms; the term "*acyl*" refers to an aliphatic saturated or unsaturated C₁ - C₂₄ acyl group, preferably an acyl group having an even number of carbon atoms, most preferably an acyl group derived from a natural fatty acid such as a saturated aliphatic acyl group selected from
15 acetyl, butyryl, caproyl, octanoyl, decanoyl, lauroyl, myristyl, palmitoyl and stearoyl, or an unsaturated aliphatic acyl group selected from palmitoleyl, oleyl, linoleyl, and ricinoleyl; and the term "*aryl*" refers to a mono- or poly-carbocyclic aryl group, most preferably phenyl, optionally substituted by C₁ - C₄ alkyl, halogen and/or hydroxy.

20 In one embodiment, Y is a hydroxyl group and X is O-oleoyl, O-benzyl, O-CH₂COOCH₂CH₃, NH-benzyl or NH-caproyl.

In another embodiment X is hydrogen and Y is O-acetyl or NH-CH₃.

The present invention further provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and, as an active ingredient, a
25 compound of the general formula I. A preferred use of said composition is for stimulation of target cells.

The *CPP* used in the invention may exert one of many neural promoting activities including but not limited to promotion of neuronal outgrowth, promotion of nerve growth, provision of dopaminotrophic supporting environment in a

diseased portion of the brain, prevention of nerve degeneration and nerve rescue. All these activities fall within the scope of neural promoting activity.

Thus, the present invention also provides a pharmaceutical composition for promoting neural activity comprising a pharmaceutical acceptable carrier and, as an
5 active ingredient, a compound of the general formula I above.

The ability of the pharmaceutical compositions of the invention to promote neuronal activity in one or more of the above ways renders them extremely useful for treatment of various disorders. Thus, the invention also provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and,
10 as an active ingredient, a compound of the general Formula I above, for the prevention or treatment of disorders and diseases which can be prevented or treated by promoting neural activity.

Such disorders may be mental disorders such as, for example, schizophrenia or dementia or disorders resulting in learning disabilities.

15 In addition, the pharmaceutical compositions of the invention may also be used for the treatment of neurodegenerative conditions involving damage to dopaminergic neural cells. Examples of such conditions are Alzheimer's disease (AD) or Parkinson's disease (PD).

Additional neurodegenerative conditions which are within the scope of the
20 present invention are such which result from exposure of an individual to harmful environmental factors such as hazardous chemicals, neurodegenerative conditions resulting from a mechanical injury (e.g. injury of the optical nerve resulting from contact of the eye with an abusive external factor), etc.

Furthermore, it is known that, following primary degeneration of nerves,
25 additional nerves present in the vicinity of the degenerated nerves undergo secondary degeneration. Treatment of an individual suffering from a primary neurodegenerative condition may prevent or reduce the appearance of secondary degeneration in additional nerves present in the vicinity of the degenerated nerves. Such treatment, termed "*nerve rescue*" is also within the scope of the present
30 invention.

Said period of time is such a period, which enables the compositions of the invention to exert their activity. This period of time may easily be determined by a person skilled in the art for each kind of composition and target cells using any of the methods described herewith. Typically, and in contrast to some known factors
5 which affect neural cells such as NGF, the period of time required for the *CPP* used in the invention to be in contact with the target cells in order to exert their effect is very short (several minutes).

In accordance with an additional aspect of the invention, a method is provided for promoting neural activity in an individual comprising administering to
10 the individual in need an effective amount of a compound of the general Formula I above.

A method for the prevention or treatment of disorders and diseases which can be prevented or treated by promoting neural activity is also provided. This method comprises administering to a person in need a therapeutically effective
15 amount of a compound of Formula I above.

The method of the invention may be used for the treatment of a variety of disorders and diseases in which the above mentioned effects are beneficial, i.e., in which the effect of the *CPP* ameliorates or reduces the undesired symptoms of the treated condition or disease. These conditions and disorders may be for example,
20 but not limited to, mental disorders such as schizophrenia or dementia, disorders leading to learning disabilities, neurodegenerative disorders such as Alzheimer or Parkinson disease and for prevention or treatment of nerve rescue following nerve injury.

25 BRIEF DESCRIPTION OF THE DRAWINGS

In order to understand the invention and to see how it may be carried out in practice, a preferred embodiment will now be described, by way of non-limiting example only, with reference to the accompanying drawings, in which:

Fig. 1 shows photographs of levels a series of proteins from CHO cells which were tyrosine, phosphorylated following the incubation of the cells with the compound 1,3 cyclic propandiol phosphate-2-methylamine of the present invention.

Fig. 2 shows a comparison indicating induction of neuronal outgrowth in
5 PC-12 cells after incubation in tissue culture with the compound β -caproylamido 1,3-cPP of the present invention compared to such cells incubated with a control.

DETAILED DESCRIPTION OF THE INVENTION

As mentioned, the present invention provides cyclic glycerophosphates (CGs), and in particular derivatives of 1,3-cyclic propandiol phosphates (CPP).
10 These new derivatives may be used for stimulating cells. In particular, the CPP of the present invention promote neural activity. Such promoting of the neural activity has therapeutic implications. The resulting induced cell activity may be used in neurodegeneration. The 1,3-cyclic propandiol phosphates and analogs thereof of the invention may generally be synthesized using any one of the methods known in
15 the art for synthesis of phosphate esters. Specific methods, which may typically be used, for preparing the cyclic phosphates of the invention are described specifically below (see Examples).

In the case of using the new CPP of the present invention for promoting neural activity, suitable pharmaceutical compositions comprising as the active
20 ingredient an efficient amount of the CPP are prepared. In addition to the active ingredient, the pharmaceutical compositions may also contain a carrier selected from any one of the carriers known in the art. The nature of the carrier will depend on the intended form of administration and indication for which the composition is used. The compositions may also comprise a number of additional ingredients such
25 as diluents, lubricants, binders, preservatives, etc.

The compositions of the invention may be administered by any suitable way. A preferred mode of their administration is either i.v., topically or per os although at times it may be advantageous to use other administration modes as well.

Typically, the pharmaceutical compositions of the invention will comprise about 1 mg to about 100 mg of the active material per kg body weight of the treated individual.

While the compositions of the invention will typically contain a single *CPP*,
5 it is possible at times to include in the composition or to co-administer two or more *CPP*, which may then act together in a synergistic or additive manner to prevent or treat the neurogenerative disorder.

The *CPP* used in the invention may be used in any of their isomer forms. For various purposes, one of the isomers may be preferred over the remaining
10 ones.

According to the invention, the *CPP* may be administered either in a single dose or may be given repetitively over a period of time.

The compositions of the invention may also be administered to the treated individual in combination with an additional treatment, e.g. wherein the treated
15 condition is a neurodegenerative one, the compositions may be given together with one of the currently available drugs or therapies used for treatment of neurodegenerative diseases such as dopamine receptor stimulants, L-dopa or together with a growth factor such as NGF. In such a combination treatment the *CPP* may be administered simultaneously with or at different times than the administration of
20 the additional treatment so as to yield a maximum preventive or therapeutic effect.

Furthermore, it should be noted that 2-dimethylamine ethyl ester 1,3-cyclic propanediol phosphate (described in Example 12 below) was designed for crossing the blood brain barrier and tests revealed that the compound is indeed able to cross the blood brain barrier. Thus such a compound may be useful for treating
25 neurodegenerative symptoms in the central nervous system as well.

EXAMPLES

The invention will now be illustrated by the following non-limiting
30 examples.

Chemical synthesis

1,3 cyclic propandiol phosphate. This compound (1,3-cPP) was prepared
5 by the procedure described (Shinitzki et al. 2000) and was dissolved in Hanks' balanced salt solution (HBSS) or cell culture medium and sterilized by filtration.

Additional cyclic phosphates of the invention are prepared using various starting materials for forming the 1,3-cyclic propandiol moiety substituted with the appropriate derivatives. The reaction of a suitable β -glyceryl derivative
10 (oleoyl, benzyl) with POCl_3 , gives the desired cyclization and yields the oleoyl and benzyl derivatives, respectively of the 1,3-cyclic propandiol ring. Serinol (2-amino-1,3-propandiol) or 1,3-cyclic propandiol phosphate are also used as starting materials for the synthesis of other derivatives as described below.

The reaction is carried out in an anhydrous solvent, e.g. dioxane or
15 methylene chloride. The synthesis of a series of novel 6-membered ring cyclic phosphates is illustrated below.

General

Free phosphates (either the acid form or the sodium salt) were prepared by the following general procedure involving the preparation of Solutions a-d:

20 **Solution a:** 0.1M of the dialcohol dissolved in freshly distilled methylene chloride.

Solution b: 0.1M of freshly distilled phosphorous oxichloride (POCl_3 , 15, 35gr or 9.35,l) dissolved in freshly distilled methylene chloride.

Solution c: Acetone-Water 9:1 (v/v).

25 **Solution d:** Acetone-0.1M aqueous sodium bicarbonate.

Procedure: To a cooled (4°C) solution a, an equi-volume of solution b was added dropwise while stirring. The temperature was then slowly raised to boiling and allowed to reflux for 406 hours. The solvent was evaporated. The residue was dissolved either in solution c (to obtain the free acid) or solution d (to obtain the

sodium salt). After 24 hours the solvent was evaporated yielding the desired crude product. Recrystallization was done from either acetone or acetonitrile.

Phosphate esters and phosphoramidates were prepared as mentioned above with the following modification. At the last step, the phosphorous monochloride derivative was further reacted in methylene chloride with an alcohol (e.g. benzyl alcohol) to obtain the respective ester of the cyclic phosphate. Alternatively it may be reacted with a primary or secondary amine and an equivalent of triethylamine to obtain the phosphoramidate of the cyclic phosphate. After evaporation the crude product was recrystallized from a water/ethanol solution.

10

Example 1: Synthesis of 1,3-cyclic propandiol phosphate-5-oleoyl

β -glyceryl mono oleate (Sigma) was reacted with equimolar amount of POCl_3 in freshly distilled dry CH_2Cl_2 under reflux for 8 hours. Hydrolysis of the remaining P-Cl bond was afforded by evaporating the solvent and redissolving the residue in acetone-aqueous sodium bicarbonate 9:1 (v/v). After 24 hour the solvent was evaporated and the product was purified by chromatography on silica gel with mixtures of chloroform-methanol-water as eluants.

15

Example 2: Synthesis of 1,3-cyclic propandiol phosphate-5-benzyloxy

β -benzyl glycerol (Sigma) was reacted with equimolar amount of POCl_3 analogously to Example 1 and purified by thin layer chromatography (TLC) of silica gel.

20

Example 3: Synthesis of 1,3-cyclic propandiol phosphate-5-benzylamino

Serinol (Aldrich) was reacted with benzyl bromide in dry CH_2Cl_2 . The product (N-benzyl serinol) was reacted with POCl_3 as in Example 1. Purification was afforded by silica gel chromatography.

25

Example 4: Synthesis of 1,3-cyclic propandiol phosphate-5-caproylamido

Caproic acid (Aldrich) and N-hydroxy succinimide (Aldrich) were reacted with dicyclohexyl carbodiimide (DCC, Aldrich) in ethyl acetate. The formed active ester caproyl hydroxy succinimide was collected in the supernatant. It was further reacted with serinol (Aldrich) in tetrahydrofuran (THF) - 0.1 M aqueous sodium bicarbonate 1:1 (V/V). The obtained caproyl amide of serinol was isolated and reacted with POCl_3 as in example 1. The product was isolated by TLC on silica gel.

Example 5: Synthesis of 1,3-cyclic propandiol phosphate-2-benzyloxy

Benzyl dichlorophosphate was prepared by mixing equimolar amounts by benzyl alcohol with POCl_3 for 1 hour at room temperature. Then one equivalent of 1,3 propanediol (Aldrich) in dry CH_2Cl_2 was added and allowed to react by reflux for 18 hours. One volume of aqueous 0.1M NaHCO_3 was then added and mixed. The CH_2Cl_2 layer which contained the product was separated and washed several times with water. The CH_2Cl_2 was evaporated and the product (oil) was collected.

Example 6: Synthesis of 1,3-cyclic propandiol phosphate-2-acetyloxy

1,3 Cyclic propanediol phosphate (1,3 cPP (Shinitzky et al. 2000 Eur. J. Biochem. 267:2547) was dissolved in acetic acid and diluted with an excess of acetic anhydride (Aldrich). The mixture was refluxed for 8 hours and then evaporated under vacuum. The product, a mixed anhydride of 1,3 cPP and acetic acid, remained as oil.

Example 7: Synthesis of 1,3-cyclic propandiol phosphate-2-methylamino

1,3 Propanediol was reacted with equimolar amounts of POCl_3 for 5 hours in CH_2Cl_2 to yield 1,3 cyclic chloropropanediol (1,3 cPP-Cl, Shinitzky et al., 2000). The solvent was evaporated and the product extracted with ether. 1,3 cPP-Cl was dissolved in tetrahydrofuran (THF) and reacted with methylamine gas for 5 hours. The THF was evaporated, the precipitate collected and the final product crystallized from isopropanol.

The compound was pure on a thin layer chromatography (n-propanol: NH₃: water, 6:3:1, R_f 0,7) and mass spectra analysis gave the predicted molecular weight.

5 **Example 8:** Synthesis of 1,3-cyclic propandiol phosphate-5-glycine ethylester.

1,3 cPP-Cl synthesized as described above was reacted with equimolar amounts of glycine ethylester and triethylamine in THF for 24 hours. The THF was evaporated and the precipitate collected. The final product was extracted with ether.

10 The compound was pure on a thin layer chromatography (chloroform: methanol: water, 68:25:4, R_f 0,76) and mass spectra analysis gave the predicted molecular weight.

Example 9: Synthesis of 1,3-cyclic propanediol phosphate

15 0.5 M solution of 1,3-propanediol (Aldrich) in freshly distilled methylene chloride was cooled to 4⁰ C. To this solution, an equimolar amount of freshly distilled POCl₃ dissolved in methylene chloride was added dropwise with stirring. The temperature was then raised slowly to boiling and kept under reflux for 6 hours. The solution was then evaporated to complete dryness and acetone-water
20 (9:1) was added. The solution was left at room temperature for 24 hours and then evaporated to dryness to obtain the acid form of the product. Crystallization was afforded from acetone or acetonitrile.

Example 10: Synthesis of 2-methyl 1,3-cyclic propanediol phosphate

25 0.5 M solution of 2-methyl 1,3-propanediol (Aldrich) was reacted with an equimolar amount of POCl₃ as in Example 9.

Example 11: Synthesis of 1-methyl 1,3-cyclic propanediol phosphate

30 0.5 M solution of 1,3-butanediol (Aldrich) was reacted with an equimolar amount of POCl₃ as in Example 9.

Example 12: Synthesis of 2-dimethylamine ethyl ester 1,3-cyclic propanediol phosphate

Distilled and dry 2- dimethylamine ethanol (Aldrich) was dissolved in dry
5 methylene chloride and an equimolar amount thereof was added to 1,3-cyclic
propanediol phosphate (prepared according to Example 9) in methylene chloride
and refluxed for 4 hours. Upon cooling the hydrochloride salt of the product
precipitated. The compound was crystallized from ethanol.

10 **Example 13:** Synthesis of 1,3-cyclic propanediol phosphoamidate

1,3-propanediol was reacted with an equimolar amount of phosphorus
oxychloride in methylene chloride and the resulting 1,3-cyclic-propanediol
phosphate-Cl was reacted with ammonia gas, yielding 1,3-cyclic-propanediol
phosphate-NH₂. The compound was pure on thin layer chromatography
15 (n-propanol: NH₃: H₂O 6: 3: 1 v/v, R_f 0.63).

Example 14: Synthesis of 1,3-cyclic propanediol N-ethyl phosphoamidate

1 equivalent of 1,3-cyclic-propanediol-phosphate-Cl as prepared in the
preceding example, was reacted with an equivalent of ethylamine in the presence
20 of equivalent of triethylamine in tetrahydrofuran. Final product was pure on TLC
(n-propanol: NH₃: H₂O 6: 3: 1 v/v).

Example 15: Synthesis of 1,3-cyclic propanediol phosphoamidate glycine
25 ethylester

1 equivalent of 1,3-cyclic-propanediol-phosphate-Cl as prepared in
Example 13, was reacted with glycine ethylester hydrochloride in the presence of
2 equivalents of triethylamine. The final product was pure on TLC (chloroform:
methanol: water 65:25:4 v/v, R_f 0,76).

30

Example 16: Synthesis of 2-benzyloxy 1,3-chloropropanediol phosphate

2-benzyloxy 1,3 propanediol (Aldrich) was reacted in equimolar amounts with phosphorus oxychloride in methylene chloride. Benzoxo 1,3-cyclic propanediol phosphate was pure on TLC (n-propanol: NH₃: H₂O 6: 3: 1 v/v, R_f 0.63).

5

Example 17: Synthesis of 2-caproimido 1,3-chloropropanediol phosphate

Caproic acid was reacted overnight with N-hydroxy succinimide (NHS) in the presence of DCC in equimolar amounts. The obtained precipitate, DCU, was separated and discarded, and the caproic acid-NHS ester was extracted from the
10 supernatant. This compound was dissolved in THF and reacted overnight with 1 equivalent of serinol dissolved in 0.1 M NaHCO₃. The solvent was evaporated and the amide of caproic acid-serinol extracted with ethyl acetate and then reacted with phosphorous oxychloride in methylene chloride. The final product was pure on TLC (chloroform:methanol:water 65:25:4 v/v, R_f 0.83).

15

Biological Activity

PC12 Cells

The immortal PC12 cell line is one of the most investigated systems in
20 neuronal differentiation. In the presence of nerve growth factor these cells differentiate to neuronal cells. PC12 cells originated from rat pheochromocytoma were grown as monolayers in Eagle's medium (EM) supplemented with 10% fetal calf serum, 50 µg/ml gentamicin and 5 mM glutamine, in a humidified incubator buffered with 5% CO₂, at 37°C. The culture medium is changed every
25 four days and the cells are passaged every eight days and performed confluent monolayers (1.5 x 10⁶ in a 10 cm plate or 10⁵ cells per well in 24 wells plate). PC12 cells are originally round cells which, following several days in the presence of nerve growth factor (NGF) process nerves. Upon withdrawal of the NGF, the nerves retract and a process of apoptosis is initiated in the cells.

30

Example 18. Cell Signaling Analysis

CHO cultures were grown as described above for PC12 cells. The cultures were divided into two groups and different compounds were added, followed by a period of incubation of from 1 to 30 minutes. Thus one CHO culture was incubated
5 with 5 μ M of 1,3-cyclic propandiol phosphate-2-methylamino at 37°C, the control being a similar CHO culture incubated with 1,3-cyclic glycerphosphate under the same conditions. Augmented tyrosine phosphorylation, noticed already after 1 minute of exposure, was induced by the presence of 1,3-cyclic propandiol phosphate-2-methylamino. In particular it was detected in a series of proteins with
10 molecular weight of \approx 35 kDa, \approx 45 kDa, \approx 60-70 kDa. as shown in Fig. 1.

Example 19. Induction of neuronal outgrowth in PC-12 cells


PC12 cells were grown in culture as explained above. The cells were divided into two groups and different compounds were added. To the first were
15 added 5 μ M 1,3-cyclic propandiol phosphate-5-caproylamido, while as a control to the second portion was added NGF. After a period of 8 days the two groups of PC12 cells were inspected by microscope. As shown in Fig. 2, comparison of the two PC12 cells reveals that the addition of 1,3-cyclic propandiol phosphate-5-caproylamido to the cells promoted neural outgrowth while the line
20 growth of the cells in which NGF was added did not exhibit such promotion of neural outgrowth.

Similar effects were observed (data not shown) for the following compounds. 1,3-Cyclic propanediol phosphate, 2-methyl 1,3-cyclic propanediol phosphate and 1-methyl 1,3-cyclic propanediol phosphate (Examples 9-11 above)
25 all of which exhibited similar activity in intracellular tyrosine phosphorylation (with Chinese Hamster Ovarian Cells, CHO cells), triggering axonal outgrowth in PC12 cells. 1,3-cyclic propanediol phosphoamidate (Example 13 above) was shown capable of inducing tyrosine phosphorylation in CHO cells, but did not induce neuronal differentiation in PC12 cells. On the other hand it did rescue them from
30 NGF deprivation. 1,3-Cyclic propanediol N-ethyl phosphoamidate (Example 14

above) promoted tyrosine phosphorylation, in CHO cells but did not induce neuronal differentiation of PC12 nor rescue from NGF deprivation. 2-Benzoyloxy 1,3-chloropropanediol phosphate (Example 16 above) was dissolved in ethanol and from there introduced by 1:1000 dilution into PC12 cultures. Strong neuronal
5 differentiation and nerve rescue was noticed. 2-Caproimido 1,3-chloropropanediol phosphate (Example 17 above) induced tyrosine phosphorylation in CHO cells and neuronal differentiation of PC12 cells.

CLAIMS:

1. A compound of the following formula (I):



- 5 or pharmaceutically acceptable salts thereof,
wherein:
n is 0 or 1;
X is hydrogen, O-R, NH-R or N-(C=O)-R;
Y is O-R₁, NH-R₁;
- 10 R is hydrogen, linear or branched alkyl, linear or branched acyl, substituted or non-substituted aryl or araalkyl residue;
R₁ is hydrogen, linear or branched alkyl, linear or branched acyl, substituted or non-substituted aryl, alkylcarboxy ester or alkyl-N-R₂R₃;
R₂ and R₃ are independently hydrogen or an alkyl group;
- 15 alkyl is an alkyl group having from 1 to 24 carbon atoms, preferably from 3 carbon atoms to 20 carbon atoms, most preferably from 5 carbon atoms to 15 carbon atoms;
wherein acyl is an aliphatic saturated or unsaturated C₁ - C₂₄ acyl group, preferably an acyl group having an even number of carbon atoms, and most
20 preferably an acyl group derived from a natural fatty acid such as a saturated aliphatic acyl group or an unsaturated aliphatic acyl group;
aryl is a to a mono- or poly-carbocyclic aryl group, most preferably phenyl, optionally substituted by C₁-C₄ -alkyl, halogen and/or hydroxy;

provided that when X is hydrogen Y is not O-R₁ wherein R₁ is hydrogen, alkyl or aryl.

2. A compound according to claim 1, wherein the acyl moiety is selected from the group comprising of acetyl, butyryl, caproyl, octanoyl, decanoyl, lauroyl, myristyl, palmitoyl and stearoyl, palmitoleyl, oleyl, linoleyl, and ricinoleyl.

3. A compound according to claim 1 wherein Y is OH and X is O-R or NH-R; wherein R is a linear or branched alkyl or linear or branched acyl.

4. A compound according to claim 1 wherein X is hydrogen and Y is O-R₁ or NH-R₁; wherein R₁ is a linear or branched acyl.

5. Compounds of formula I according to claim 1 selected from the group consisting of:

- (a) 1,3-cyclic propandiol phosphate-5-oleoyl;
 - (b) 1,3-cyclic propandiol phosphate-5- benzyloxy;
 - (c) 1,3-cyclic propandiol phosphate-5- benzylamino;
 - (d) 1,3-cyclic propandiol phosphate-5- caproylamido;
 - (e) 1,3-cyclic propandiol phosphate-2-benzyloxy;
 - (f) 1,3-cyclic propandiol phosphate-2- acetyloxy;
 - (g) 1,3-cyclic propandiol phosphate-2-methylamino;
 - (h) 1,3-cyclic propandiol phosphate-5-glycine ethylester;
 - (i) 2-methyl 1,3-cyclic propanediol phosphate;
 - (j) 1-methyl 1,3-cyclic propanediol phosphate;
 - (k) 2-dimethylamine ethyl ester 1,3-cyclic propanediol phosphate;
 - (l) 1,3-cyclic propanediol phosphoamidate;
 - (m) 1,3-cyclic propanediol N-ethyl phosphoamidate;
 - (n) 1,3-cyclic propanediol phosphoamidate glycine ethylester;
 - (o) 2-benzyloxy 1,3-chloropropanediol phosphate;
 - (p) 2-caproimido 1,3-chloropropanediol phosphate;
- or pharmaceutically acceptable salts thereof.

6. A pharmaceutical composition comprising a pharmaceutical acceptable carrier and, as an active ingredient, a compound of the general formula (I) in claim 1 or pharmaceutically acceptable salt thereof.

7. A pharmaceutical composition according to claim 6, for promoting neural
5 activity.

8. A pharmaceutical composition according to claim 7, wherein said neural activity is selected from the group consisting of promotion of neuronal outgrowth, promotion of nerve growth, provision of dopaminotrophic supporting environment in a diseased portion of the brain, prevention of nerve degeneration and nerve
10 rescue.

9. A pharmaceutical composition according to claim 6, for the prevention or treatment of disorders and diseases which can be prevented or treated by activating neural cells.

10. A pharmaceutical composition according to claim 8, wherein said disorder
15 and disease are schizophrenia, dementia or disorder resulting from learning disabilities.

11. A pharmaceutical composition according to any one of claims 6 to 10 wherein the compound of formula I is selected from the group consisting of

- (a) 1,3-cyclic propandiol phosphate-5-oleoyl;
- 20 (b) 1,3-cyclic propandiol phosphate-5- benzyloxy;
- (c) 1,3-cyclic propandiol phosphate-5- benzylamino;
- (d) 1,3-cyclic propandiol phosphate-5- caproylamido;
- (e) 1,3-cyclic propandiol phosphate-2-benzyloxy;
- (f) 1,3-cyclic propandiol phosphate-2- acetyloxy;
- 25 (g) 1,3-cyclic propandiol phosphate-2-methylamino;
- (h) 1,3-cyclic propandiol phosphate-5-glycine ethylester;
- (i) 2-methyl 1,3-cyclic propanediol phosphate;
- (j) 1-methyl 1,3-cyclic propanediol phosphate;
- (k) 2-dimethylamine ethyl ester 1,3-cyclic propanediol phosphate;
- 30 (l) 1,3-cyclic propanediol phosphoamidate;

- (m) 1,3-cyclic propanediol N-ethyl phosphoamidate;
- (n) 1,3-cyclic propanediol phosphoamidate glycine ethylester;
- (o) 2-benzyloxy 1,3-chloropropanediol phosphate;
- (p) 2-caproimido 1,3-chloropropanediol phosphate;

5 or pharmaceutically acceptable salts thereof.

12. Use of a compound of formula I for the preparation of a medicament for treating disorders and diseases which can be prevented or treated by activating neural cells, substantially as described in the specification.

13. Use according to claim 12, wherein said neural activity is selected from the
10 group consisting of promotion of neuronal outgrowth, promotion of nerve growth, provision of dopaminotrophic supporting environment in a diseased portion of the brain, prevention of nerve degeneration and nerve rescue.

15

20

25

30

- 23 -

Figure 1:





Figure 1: Level of tyrosine-phosphorylated proteins in CHO cells after pulsing for different time intervals at 37 °C with 5 μ M of 1,3 cPP-NH-CH₃. Detection was with monoclonal anti-phosphotyrosine IgG followed by ECL staining. Arrows indicate the most affected bands.

- 25 -

Figure 2:



5